curevac biontech - Search News

Order byBest matchMost fresh

News

BioNTech to buy German rival CureVac for $1.25B

· 2d · on MSN

BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.

Continue reading

MedCity News · 2d

BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute

PharmTech · 1d

CureVac to Be Acquired by BioNTech in $1.25B Deal to Advance mRNA Cancer Therapies

GlobalData on MSN2d

BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition

BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its ...

3d

BioNTech to Buy CureVac for $1.25 Billion for Cancer Boost

BioNTech SE agreed to buy former Covid vaccine rival CureVac NV for about $1.25 billion in an all-stock transaction that will ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results